Open comment allows for key stakeholders to critically review and identify any errors or gaps in a draft guideline prior to its finalization and publication. It allows for greater transparency in the ASCO guideline development process and complies with the Institute of Medicine (IOM) and Council for Medical Specialty Societies (CMSS) standards for guideline development. In addition, open comment enables ASCO to engage interested stakeholders (especially patients/patient advocacy groups), provide a higher-quality product to the membership, and facilitate implementation and dissemination efforts.
ASCO Guidelines will be available for open comment for a 2- to 3-week period. Prospective reviewers must contact ASCO to request to review the draft guideline recommendations and they will be required to sign a non-disclosure and confidentiality agreement before receiving the draft guideline recommendations. Reviewers must identify themselves by name and affiliation; anonymous comments will not be accepted. Guidelines staff will review and summarize comments and bring relevant comments to the guideline panel chairs, and to the entire panel if necessary. Any changes made from the open comment process will be reviewed by the entire panel prior to ASCO Clinical Practice Guidelines Committee (CPGC) approval. Comments are advisory only and ASCO is not bound to make any changes based on feedback from open comment. ASCO will not respond to reviewers or post any responses to comments.
Available for Open Comment
- Chemo- and Targeted Therapy for Patients with HER2-Negative Metastatic Breast Cancer that is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update is available for open comment from April 12, 2021, to April 26, 2021.